Research & Development: Page 3

  • Doctor works on HUD or graphic display in front of her
    Image attribution tooltip
    Ignatiev via Getty Images
    Image attribution tooltip
    Sponsored by Pfizer

    Harnessing the power of AI to detect ATTR-CM

    From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

    March 31, 2025
  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

    The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.

    By • March 28, 2025
  • exploding pills Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Big Pharma Business Strategies

    Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles. 

    By PharmaVoice staff
  • The HHS in DC
    Image attribution tooltip
    Alex Wong / Staff via Getty Images
    Image attribution tooltip

    HHS announces sweeping reorganization, including cuts of 10K workers

    Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

    By Rebecca Pifer • March 27, 2025
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images
    Image attribution tooltip

    How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

    After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

    By • March 27, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/PharmaVoice
    Image attribution tooltip

    Biogen plots new global headquarters in Kendall Square

    The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

    By Jacob Bell • March 25, 2025
  • Ruxandra Draghia-Akli
    Image attribution tooltip
    Permission granted by Novavax
    Image attribution tooltip
    Profile

    The industry heavyweight behind Novavax’s push to bounce back

    As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

    By Alexandra Pecci • March 25, 2025
  • biotech stealth
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotechs emerging from stealth take aim at pharma’s prime targets

    The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

    By Kelly Bilodeau • March 24, 2025
  • recession
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How pharma could feel the pain of a recession

    Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

    By • March 21, 2025
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

    The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

    By • March 20, 2025
  • china biotech
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The key factors shaping China’s biopharma boom

    Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

    By Alexandra Pecci • March 19, 2025
  • Jay Hartenbach, COO, president, Diakanos Oncology
    Image attribution tooltip
    Permission granted by Diakanos
    Image attribution tooltip
    Q&A

    How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

    Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

    By • March 18, 2025
  • radioactive syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

    Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

    By Kelly Bilodeau • March 17, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Q&A

    Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

    The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

    By • March 17, 2025
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Takeda’s $770M deal deepens Big Pharma’s omics push

    The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

    By Alexandra Pecci • March 13, 2025
  • brain design with neuro points scattered
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

    Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

    By • March 11, 2025
  • Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    What’s driving pharma’s layoffs in 2025

    Familiar foes in the industry have claimed a slew of jobs in recent months.

    By • March 10, 2025
  • A podium showing the logo for the Centers for Disease Control and Prevention is seen.
    Image attribution tooltip
    Kevin C. Cox via Getty Images
    Image attribution tooltip

    The top 3 impacts of Trump’s health data purge

    Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

    By Michael Brady • March 6, 2025
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    With patent losses on the horizon, Amgen refocuses its business strategy

    The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

    By Alexandra Pecci • March 5, 2025
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie gets into obesity with $350M deal for once-weekly shot

    A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

    By Jonathan Gardner • March 5, 2025
  • Pill pop art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Americans want to participate in clinical trials — so why don’t they?

    A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

    By Kelly Bilodeau • March 4, 2025
  • Toby Ferguson, chief medical officer, Voyager Therapeutics
    Image attribution tooltip
    Permission granted by Voyager Therapeutics
    Image attribution tooltip

    New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

    Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

    By • March 4, 2025
  • Teva
    Image attribution tooltip
    Permission granted by Teva
    Image attribution tooltip

    Teva targets schizophrenia to build on innovative medicines growth

    The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

    By • Feb. 28, 2025
  • Ben Taylor, CFO, Recursion Pharmaceuticals
    Image attribution tooltip
    Permission granted by Recursion
    Image attribution tooltip
    Q&A

    AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

    Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

    By • Feb. 27, 2025
  • Cancer vaccine
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Cancer vaccines have stumbled, but the approach is gaining new steam

    The number of candidates in development has nearly doubled over the past 15 years.

    By Kelly Bilodeau • Feb. 26, 2025
  • hands pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

    Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

    By Alexandra Pecci • Feb. 25, 2025